However, while the inhibition of TGFβ signaling has demonstrated promising outcomes in mouse models and in vitro studies, including breast cancer models, effectively preventing EMT induction and immune evasion [23–30], clinical trials have regrettably failed to convincingly replicate these findings across different tumor types. Here, TGFB1 is linked to neoplasm.